DataVXJournal of Nanoparticle ResearchPaper
journal article·2025-04

Scaling nanopharmaceutical production for personalized medicine: challenges and strategies

Carolina de Souza Cardoso Delfino, Michelle Colão de Paula Pereira, Marcella dos Santos Oliveira, Isabela de Carvalho Favareto, Viviane Silva Valladão, Milena de Oliveira Mota, Maria Victória Barros Costa, Ariane Jesus Sousa-Batista, Tiago Albertini Balbino

Journal of Nanoparticle Research· Volume 27· Issue 4
Publisher page
Bibliographic record

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

Nanomaterials

OpenAlex topics: Nanoparticle-Based Drug Delivery · 3D Printing in Biomedical Research · Innovative Microfluidic and Catalytic Techniques Innovation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Zhang J, Wang S, Zhang D, He X, Wang X, Han H, Qin Y (2023) Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors. Front Immunol 14:1230893. https://doi.org/10.3389/fimmu.2023.123089310.3389/fimmu.2023.1230893 ↗
2. Chung SW, Hil-lal TA, Byun Y (2012) Strategies for non-invasive delivery of biologics. J Drug Target 20:481–501. https://doi.org/10.3109/1061186X.2012.69349910.3109/1061186X.2012.693499 ↗
3. Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, Zeb A (2017). Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. 7291–7309. https://doi.org/10.2147/IJN.S14631510.2147/IJN.S146315 ↗
4. Rizvi SZH, Shah FA, Khan N, Muhammad I, Ali KH, Ansari MM, Din FU, Qureshi OS, Kim KW, Choe YH (2019) Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in hyperlipidemia animal model. Int J Pharm 560:136–143. https://doi.org/10.1016/j.ijpharm.2019.02.00210.1016/j.ijpharm.2019.02.002 ↗
5. Souto EB, Souto SB, Campos JR, Severino P, Pashirova TN, Zakharova LY, Silva AM, Durazzo A, Lucarini M, Izzo AA (2019) Nanoparticle delivery systems in the treatment of diabetes complications. Molecules 24:4209. https://doi.org/10.3390/molecules2423420910.3390/molecules24234209 ↗
6. Rizvi-Syed AA, Ayman MS (2018) Applications of nanoparticle systems in drug delivery technologY. Saudi Pharmaceutical Journal 26:64–70. https://doi.org/10.1016/j.jsps.2017.10.01210.1016/j.jsps.2017.10.012 ↗
7. Bahrami B, Hojjat-Farsangi M, Mohammadi H, Anvari E, Ghalamfarsa G, Yousefi M, Jadidi-Niaragh F (2017) Nanoparticles and targeted drug delivery in cancer therapy. Immunol Lett 190:64–83. https://doi.org/10.1016/j.imlet.2017.07.01510.1016/j.imlet.2017.07.015 ↗
8. Smith BR, Edelman ER (2023) Nanomedicines for cardiovascular disease. Nature Cardiovascular Research 2:351–367. https://doi.org/10.1038/s44161-023-00232-y10.1038/s44161-023-00232-y ↗
9. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751. https://doi.org/10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
10. Yu M, Wu J, Shi J, Farokhzad OC (2016) Nanotechnology for protein delivery: overview and perspectives. J Control Release 240:24–37. https://doi.org/10.1016/j.jconrel.2015.10.01210.1016/j.jconrel.2015.10.012 ↗
11. Couvreur P, Vauthier C (2006) Nanotechnology: intelligent design to treat complex disease. Pharm Res 3:1417–1450. https://doi.org/10.1007/s11095-006-0284-810.1007/s11095-006-0284-8 ↗
12. Jia Y, Jiang Y, He Y, Zhang W, Zou J, Magar KT, He W (2023) Approved nanomedicine against diseases Pharmaceutics 15:774. https://doi.org/10.3390/pharmaceutics1503077410.3390/pharmaceutics15030774 ↗
13. Zeb A, Rana I, Choi HI, Lee CH, Baek SW, Lim CW, Kim JK (2020) Potential and applications of nanocarriers for efficient delivery of biopharmaceuticals. Pharmaceutics 12:1184. https://doi.org/10.3390/pharmaceutics1212118410.3390/pharmaceutics12121184 ↗
14. Lu W, Yao J, Zhu X, Qi Y (2021) Nanomedicines: redefining traditional medicine. Biomed Pharmacother 134:111103. https://doi.org/10.1016/j.biopha.2020.11110310.1016/j.biopha.2020.111103 ↗
15. Souto EB, Silva GF, Dias-Ferreira J, Zielinska A, Ventura F, Durazzo A, Santini A (2020) Nanopharmaceutics: part II—production scales and clinically compliant production methods. Nanomaterials 10:455. https://doi.org/10.3390/nano1003045510.3390/nano10030455 ↗
16. Miao X, Yang W, Feng T, Lin J, Huang P (2018) Drug nanocrystals for cancer therapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 10:e1499. https://doi.org/10.1002/wnan.149910.1002/wnan.1499 ↗
17. Kumar R, Dalvi SV, Siril PF (2020) Nanoparticle-based drugs and formulations: current status and emerging applications. ACS Applied Nano Materials 3:4944–4961. https://doi.org/10.1021/acsanm.0c0060610.1021/acsanm.0c00606 ↗
18. Ani AC, Emencheta SC, Orah KJ, Upaganlawar AB, Prajapati BG, Oranu CK, Onyekwe CP (2024). Targeted nanotechnology-based formulations. In Alzheimer’s Disease and Advanced Drug Delivery Strategies, 47–359. https://doi.org/10.1016/B978-0-443-13205-6.00007-810.1016/B978-0-443-13205-6.00007-8 ↗
19. Guo P, Huang J, Zhao Y, Martin CR, Zare RN, Moses MA (2018) Nanomaterial preparation by extrusion through nanoporous membranes. Small 14:1703493. https://doi.org/10.1002/smll.20170349310.1002/smll.201703493 ↗
20. Le Corre D, Bras J, Dufresne A (2010) Starch nanoparticles: a review. Biomacromol 11:1139–1153. https://doi.org/10.1021/bm901428y10.1021/bm901428y ↗
21. Vauthier C, Bouchemal K (2009) Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 26:1025–1058. https://doi.org/10.1007/s11095-008-9800-310.1007/s11095-008-9800-3 ↗
22. Mendoza-Muñoz N, Quintanar-Guerrero D, Allémann E (2012) The impact of the salting-out technique on the preparation of colloidal particulate systems for pharmaceutical applications. Recent Pat Drug Delivery Formulation 6:236–249. https://doi.org/10.2174/18722111280265268810.2174/187221112802652688 ↗
23. Pedroso-Santana S, Fleitas-Salazar N (2020) Ionotropic gelation method in the synthesis of nanoparticles/microparticles for biomedical purposes. Polym Int 69:443–447. https://doi.org/10.1002/pi.597010.1002/pi.5970 ↗
24. Tiruwa R (2016) A review on nanoparticles-preparation and evaluation parameters. Indian J Pharm Biol Res 4(2):27. https://doi.org/10.1021/acs.chemmater.6b0473810.1021/acs.chemmater.6b04738 ↗
25. Rao JP, Geckeler KE (2011) Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci 36:887–913. https://doi.org/10.1016/j.progpolymsci.2011.01.00110.1016/j.progpolymsci.2011.01.001 ↗
26. Mehnert W, Mäder K (2012) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 64:83–101. https://doi.org/10.1016/S0169-409X(01)00105-310.1016/S0169-409X(01)00105-3 ↗
27. Yadav N, Khatak S, Sara US (2013). Solid lipid nanoparticles-a review. Int. J. Appl. Pharm, 5:8–18. ISSN: 0975–7058
28. Khairnar SV, Pagare P, Thakre A, Nambiar AR, Junnuthula V, Abraham MC, Dyawanapelly S (2022) Review on the scale-up methods for the preparation of solid lipid nanoparticles. Pharmaceutics 14:1886. https://doi.org/10.3390/pharmaceutics1409188610.3390/pharmaceutics14091886 ↗
29. Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M (2022) Scale-up polymeric-based nanoparticles drug delivery systems: development and challenges. OpenNano 7:100048. https://doi.org/10.1016/j.onano.2022.10004810.1016/j.onano.2022.100048 ↗
30. Malik S, Muhammad K, Waheed Y (2023) Nanotechnology: a revolution in modern industry. Molecules 28:661. https://doi.org/10.3390/molecules2802066110.3390/molecules28020661 ↗
31. Operti MC, Bernhardt A, Grimm S, Engel A, Figdor CG, Tagit O (2021) PLGA-based nanomedicines manufacturing: technologies overview and challenges in industrial scale-up. Int J Pharm 605:120807. https://doi.org/10.1016/j.ijpharm.2021.12080710.1016/j.ijpharm.2021.120807 ↗
32. Agrahari V, Hiremath P (2017) Challenges associated and approaches for successful translation of nanomedicines into commercial products. Nanomedicine 12:819–82310.2217/nnm-2017-0039 ↗
33. Zheng C, Li M, Ding J (2021) Challenges and opportunities of nanomedicines in clinical translation. Bio Integration 2:57–6010.15212/bioi-2021-0016 ↗
34. Verpoort F, Ahmad I, Ahmad A, Khan A, Chee CY (2021) Nanomedicine manufacturing and applications. Elsevier. https://doi.org/10.1016/C2019-0-02508-310.1016/C2019-0-02508-3 ↗
35. MedlinePlus (2022). What is the difference between precision medicine and personalized medicine? What about pharmacogenomics?. Bethesda (MD): National Library of Medicine (US); [Last updated May 17, 2022]. Available from: https://medlineplus.gov/genetics/understanding/precisionmedicine/precisionvspersonalized/
36. Yamamoto Y, Kanayama N, Nakayama Y, Matsushima N (2022) Current status, issues and future prospects of personalized medicine for each disease. J Personalized Med 12:444. https://doi.org/10.3390/jpm1203044410.3390/jpm12030444 ↗
37. Pirmohamed M (2023) Pharmacogenomics: current status and future perspectives. Nat Rev Genet 24:350–362. https://doi.org/10.1038/s41576-022-00572-810.1038/s41576-022-00572-8 ↗
38. Sadee W, Wang D, Hartmann K, Toland AE (2023) Pharmacogenomics: driving personalized medicine. Pharmacol Rev 75:789–814. https://doi.org/10.1124/pharmrev.122.00081010.1124/pharmrev.122.000810 ↗
39. Gdowski A, Johnson K, Shah S, Gryczynski I, Vishwanatha J, Ranjan A (2018) Optimization and scale up of microfluidic nanolipomer production method for preclinical and potential clinical trials. J Nanobiotechnology 16:12. https://doi.org/10.1186/s12951-018-0339-010.1186/s12951-018-0339-0 ↗
40. Sommonte F, Denora N, Lamprou DA (2023) Combining 3D printing and microfluidic techniques: a powerful synergy for nanomedicine. Pharmaceuticals 16:69. https://doi.org/10.3390/ph1601006910.3390/ph16010069 ↗
41. Ma Z, Li B, Peng J, Gao D (2022) Recent development of drug delivery systems through microfluidics: from synthesis to evaluation. Pharmaceutics 14:434. https://doi.org/10.3390/pharmaceutics1402043410.3390/pharmaceutics14020434 ↗
42. Wang Q, Yu Y, Chang Y, Xu X, Wu M, Ediriweera GR, Peng H, Zhen X, Jiang X, Searles DJ, Fu C, Whittaker AK (2023) Fluoropolymer-MOF hybrids with switchable hydrophilicity for 19F MRI-monitored cancer therapy. Am Chem Soc Nano 17:8483–8498. https://doi.org/10.1021/acsnano.3c0069410.1021/acsnano.3c00694 ↗
43. Wang X, Hong XZ, Li YW, Li Y, Yang J, Chen P, Liu BF (2022) Microfluidics-based strategies for molecular diagnostics of infectious diseases. Mil Med Res 9:11. https://doi.org/10.1186/s40779-022-00374-310.1186/s40779-022-00374-3 ↗
44. Shanmugasundaram KB, Li J, Sina AI, Wuethrich A, Trau M (2022) Toward precision oncology: SERS microfluidic systems for multiplex biomarker analysis in liquid biopsy. Mater Adv 3:1459–1471. https://doi.org/10.1039/D1MA00848J10.1039/D1MA00848J ↗
45. Dedeloudi A, Weaver E, Lamprou DA (2023) Machine learning in additive manufacturing & microfluidics for smarter and safer drug delivery systems. Int J Pharm 636:122818. https://doi.org/10.1016/j.ijpharm.2023.12281810.1016/j.ijpharm.2023.122818 ↗
46. Chiu FY, Yen Y (2023) Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives. Biomark Res 11:35. https://doi.org/10.1186/s40364-023-00476-710.1186/s40364-023-00476-7 ↗
47. Ye Q, Raese RA, Luo D, Feng J, Xin W, Dong C, Qian Y, Guo NL (2023) MicroRNA-Based discovery of biomarkers, therapeutic targets, and repositioning drugs for breast cancer. Cells 12:1917. https://doi.org/10.3390/cells1214191710.3390/cells12141917 ↗
48. Jaskulski S, Nuszbaum C, Michels KB (2023). Components, prospects and challenges of personalized prevention. Frontiers in Public Health, 16 February 2023 Sec. Public Health Education Promot. 11. https://doi.org/10.3389/fpubh.2023.1075076.10.3389/fpubh.2023.1075076 ↗
49. Neagu AN, Whitham D, Bruno P, Morrissiey H, Darie CA, Darie CC (2023) Omics-based investigations of breast cancer. Molecules 28:4768. https://doi.org/10.3390/molecules2812476810.3390/molecules28124768 ↗
50. Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, Amero P, Rodriguez-Aguayo C (2023) Targeting miRNAs and other non-coding RNAs as a therapeutic approach: an update. Non-Coding RNA 9:27. https://doi.org/10.3390/ncrna902002710.3390/ncrna9020027 ↗
51. Luo M, Liu Y, Xu X, Liu K, Shen C, Hu H, He Z, Wu F (2023). Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 14. https://doi.org/10.3389/fphar.2023.115827410.3389/fphar.2023.1158274 ↗
52. Sun B, Wu W, Narasipura EA, Ma Y, Yu C, Fenton OS, Song H (2023). Engineering nanoparticle toolkits for mRNA delivery. Adv Drug Deliv Rev. 200 https://doi.org/10.1016/j.addr.2023.11504210.1016/j.addr.2023.115042 ↗
53. Chehelgerdi M, Chehelgerdi M (2023) The use of RNA-based treatments in the field of cancer immunotherapy. Mol Cancer 22:106. https://doi.org/10.1186/s12943-023-01807-w10.1186/s12943-023-01807-w ↗
54. Das R, Hyer RN, Burton P, Miller JM, Kuter BJ (2023). Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape. Human Vaccines & Immunotherapeutics. 19(1). https://doi.org/10.1080/21645515.2022.2153532.10.1080/21645515.2022.2153532 ↗
55. Liu Z, Jiang W, Nam J, Moon JJ, Kim BYS (2018) Immunomodulating nanomedicine for cancer therapy. Nano Lett 18(11):6655–6659. https://doi.org/10.1021/acs.nanolett.8b0234010.1021/acs.nanolett.8b02340 ↗
56. Kuai R, Ochyl LJ, Bahjat KS, Schwenderman A, Moon JJ (2017) Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater 16:489–496. https://doi.org/10.1038/nmat482210.1038/nmat4822 ↗
57. Matz SC, Beck ED, Atherton OE, White M, Rauthmann JF, Mroczek D, Kim M, Bogg T (2023) Personality science in the digital age: the promises and challenges of psychological targeting for personalized behavior-change interventions at scale. Perspect Psychol Sci. https://doi.org/10.1177/1745691623119177410.1177/17456916231191774 ↗
58. Ahmed Z, Mohamed K, Zeeshan S, Dong X (2020). Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database 2020 baaa010. https://doi.org/10.1093/database/baaa010.10.1093/database/baaa010 ↗
59. Tan P, Chen X, Zhang H, Wei Q, Luo K (2023) Artificial intelligence aids in development of nanomedicines for cancer management. Semin Cancer Biol 89:61–75. https://doi.org/10.1016/j.semcancer.2023.01.00510.1016/j.semcancer.2023.01.005 ↗
60. Fosse V, Oldoni E, Bietrix F, Budillon A, Daskalopoulos EP, Fratelli M, Ferlach B, Groenen PMA, Hölter SM, Menon JML, Mobasheri A, Osborne N, Ritskes-Hoitinga M, Ryll B, Schmitt E, Ussi A, Andreu AL, McCormack E, PERMIT group (2023). Recommendations for robust and reproducible preclinical research in personalized medicine. BMC Medicine, 21 14. https://doi.org/10.1186/s12916-022-02719-010.1186/s12916-022-02719-0 ↗
61. De A, Ko YT (2022) Single pot organic solvent-free thermocycling technology for siRNA-ionizable LNPs: a proof-of-concept approach for alternative to microfluidics. Drug Delivery 29(1):2644–2657. https://doi.org/10.1080/10717544.2022.210852310.1080/10717544.2022.2108523 ↗
62. Chung CCY, Hong Kong Genome Project, Chu, ATW, Chung BHY (2022). Rare disease emerging as a global public health priority. Frontiers in Public Health 18 October 2022 Sec. Public Health Policy. 10. https://doi.org/10.3389/fpubh.2022.1028545.10.3389/fpubh.2022.1028545 ↗
63. Tawfik SM, Elhosseiny AA, Galal AA, William MB, Qansuwa E, Elbaz RM, Salama M (2023) Health inequity in genomic personalized medicine in underrepresented populations: a look at the current evidence. Funct Integr Genomics 23:54. https://doi.org/10.1007/s10142-023-00979-410.1007/s10142-023-00979-4 ↗
64. Koleva-Kolarova R, Buchanan J, Vellekoop H, Huygens S, Versteegh M, Mölken MRV, Szilberhorn L, Zelei T, Nagy B, Wordsworth S, Tsiachristas A (2022) Financing and reimbursement models for personalized medicine: a systematic review to identify current models and future options. Appl Health Econ Health Policy 20:501–524. https://doi.org/10.1007/s40258-021-00714-910.1007/s40258-021-00714-9 ↗
65. Cauchon NS, Oghamian S, Hassanpour S, Abernathy M (2019). Innovation in chemistry, manufacturing, and controls—a regulatory perspective from industry. J Pharm Sci 108 7. https://doi.org/10.1016/j.xphs.2019.02.00710.1016/j.xphs.2019.02.007 ↗
66. Abdelkader A, Fathi HA, Hamad MA, Elsabahy M (2020) Nanomedicine: a new paradigm to overcome drug incompatibilities. J Pharm Pharmacol 72(10):1289–1305. https://doi.org/10.1111/jphp.1329210.1111/jphp.13292 ↗
67. Vetten MA, Yah CS, Singh T, Gulumian M (2014) Challenges facing sterilization and depyrogenation of nanoparticles: effects on structural stability and biomedical applications. Nanomedicine Nanotechnol Biol Med 10(7):1391–1399. https://doi.org/10.1016/j.nano.2014.03.01710.1016/j.nano.2014.03.017 ↗
68. Halwani AA (2022) Development of pharmaceutical nanomedicines: from the bench to the market. Pharmaceutics 14:106. https://doi.org/10.3390/pharmaceutics1401010610.3390/pharmaceutics14010106 ↗
69. Vetten M, Gulumian M (2021) Sterility evaluation of targeted nanoparticles. Drug delivery with targeted nanoparticles in vitro and in vivo evaluation methods. Jenny Stanford Publishing. First Edition. ISBN: 978100316473910.1201/9781003164739-13 ↗
70. Bernal-Chávez SA, Prado-Audelo MLDP, Caballero-Florán IH, Giraldo-Gomez DM, Figueroa-Gonzalez G, Reyes-Hernandez OD, Carmen MG, González-Torres M, Cortés H, Leyva-Gomez G (2021) Insights into terminal sterilization processes of nanoparticles for biomedical applications. Molecules 26(7):2068. https://doi.org/10.3390/molecules2607206810.3390/molecules26072068 ↗
71. Johny J, Halteren CERV, Zwiehoff S, Behrends C, Bäumer C, Timmermann B, Rehbock C, Barcikowski S (2022) Impact of sterilization on the colloidal stability of ligand-free gold nanoparticles for biomedical applications. Langmuir 38(43):13030–13047. https://doi.org/10.1021/acs.langmuir.2c0155710.1021/acs.langmuir.2c01557 ↗
72. Vette MA, Yah CS, Singh T, Gulumian M (2014) Challenges facing sterilization and depyrogenation of nanoparticles: effects on structural stability and biomedical applications. Nanomedicine Nanotechnol Biol Med 10(7):1391–1399. https://doi.org/10.1016/j.nano.2014.03.01710.1016/j.nano.2014.03.017 ↗
73. Gao L, Shi X, Wu X (2021) Applications and challenges of low-temperature plasma in the pharmaceutical field. J Pharm Anal 11(1):28–36. https://doi.org/10.1016/j.jpha.2020.05.00110.1016/j.jpha.2020.05.001 ↗
74. Lombardo D, Kiselev MA (2022) Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application. Pharmaceutics 14(543):2023. https://doi.org/10.3390/pharmaceutics14030543.(Accessed:3September10.3390/pharmaceutics14030543.(Accessed:3September ↗
75. Xu K, Li S, Zhou Y, Gao X, Mei J, Liu Y (2023) Application of computing as a high-practicability and efficiency auxiliary tool in nanodrugs discovery. Pharmaceutics 15:1064. https://doi.org/10.3390/pharmaceutics1504106410.3390/pharmaceutics15041064 ↗
76. Mi XJ, Park HR, Dhandapani S, Lee S, Kim YJ (2022) Biologically synthesis of gold nanoparticles using Cirsium japonicum var maackii extract and the study of anti-cancer properties on AGS gastric cancer cells. Int J Biol Sci. 18(15):5809–5826. https://doi.org/10.7150/ijbs.7773410.7150/ijbs.77734 ↗
77. Shi J, Kantoff PW, Wooster R, Farokhzad OC (2017) Cancer nanomedicine: progress, challenges and opportunities. Nat Rev 17:20–37. https://doi.org/10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
78. Mei H, Cai S, Huang D, Gao H, Cao J, He B (2022) Carrier-free nanodrugs with efficient drug delivery and release for cancer therapy: from intrinsic physicochemical properties to external modification. Bioactive Materials 8:220–240. https://doi.org/10.1016/j.bioactmat.2021.06.03510.1016/j.bioactmat.2021.06.035 ↗
79. Chen Q, Bai L, Zhou X, Xu P, Li X, Xu H, Zheng Y, Zhao Y, Lu S, Xue M (2020) Development of long-circulating lapachol nanoparticles: formation, characterization, pharmacokinetics, distribution and cytotoxicity. RSC Adv 10:30025. https://doi.org/10.1039/D0RA05752E10.1039/D0RA05752E ↗
80. Domingues C, Santos A, Alvarez-Lorenzo C, Concheiro A, Jarak I, Veiga F, Barbosa I, Dourado M, Figueiras A (2022) Where is nano today and where is it headed? A review of nanomedicine and the dilemma of nanotoxicology. ACS Nano 16:9994–10041. https://doi.org/10.1021/acsnano.2c0012810.1021/acsnano.2c00128 ↗
81. Kim HS, Lee DY (2021) Smart engineering of gold nanoparticles to improve intestinal barrier penetration. J Ind Eng Chem 102:122–134. https://doi.org/10.1016/j.jiec.2021.06.03210.1016/j.jiec.2021.06.032 ↗
82. Ragelle H, Danhier F, Préat V, Langer R, Anderson DG (2017) Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert Opin Drug Deliv 14(7):851–864. https://doi.org/10.1080/17425247.2016.124418710.1080/17425247.2016.1244187 ↗
83. Szebeni J, Simberg D, González-Fernández Á, Barenholz Y, Dobrovolskaia MA (2018) Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat Nanotechnol 13:1100–1108. https://doi.org/10.1038/s41565-018-0273-110.1038/s41565-018-0273-1 ↗
84. D’Mello SR, Cruz CN, Chen M, Kapoor M, Lee SL, Tyner KM (2017) The evolving landscape of drug products containing nanomaterials in the United States. Nat Nanotechnol 12(6):523–529. https://doi.org/10.1038/nnano.2017.6710.1038/nnano.2017.67 ↗
85. Bueno J (2020) ADMETox: bringing nanotechnology closer to Lipinski’s rule of five. Preclinical Eval Antimicrob Nanodrugs. 61–74. https://doi.org/10.1007/978-3-030-43855-5_510.1007/978-3-030-43855-5_5 ↗
86. Kapoor D, Sharma S, Verma K, Bisht A, Sharma M, Singhai NJ, Raval N, Maheshwari R (2022) Quality-by-design-based engineered liposomal nanomedicines to treat cancer: an in-depth analysis. Nanomedicine 17(17):1173–1189. https://doi.org/10.2217/nnm-2022-006910.2217/nnm-2022-0069 ↗
87. Ali F, Neha K, Parveen S (2023) Current regulatory landscape of nanomaterials and nanomedicines: a global perspective. J Drug Deliv Sci Technol 80:104118. https://doi.org/10.1016/j.jddst.2022.10411810.1016/j.jddst.2022.104118 ↗
88. Mustapa MFM, Berker D, McGregor JM, Exton LS, Hughes BR, Levell NJ (2020) Suspension of marketing authorization for ingenol mebutate. British J Dermatol 183(4):792. https://doi.org/10.1111/bjd.1933010.1111/bjd.19330 ↗
89. Chavez-Hernandez JA, Velarde-Salcedo AJ, Navarro-Tovar G, Gonzalez C (2024) Safe nanomaterials: from their use, application and disposal to regulations. Nanoscale Adv. https://doi.org/10.1039/D3NA01097J10.1039/D3NA01097J ↗
90. Rahalkar H, Sheppard A, Santos GML, Dasgupta C, Perez-Tapia SM, Lopez-Morales CA, Salek S (2021) Current regulatory requirements for biosimilars in six member countries of BRICS-TM: challenges and opportunities. Front Med 8:726660. https://doi.org/10.3389/fmed.2021.72666010.3389/fmed.2021.726660 ↗
91. Siegrist S, Cörek E, Detampel P, Sandström J, Wick P, Huwyler J (2019) Preclinical hazard evaluation strategy for nanomedicines. Nanotoxicology 13(1):73–99. https://doi.org/10.1080/17435390.2018.150500010.1080/17435390.2018.1505000 ↗
92. Chrishtop VV, Prilepskii AY, Nikonorova VG, Mironov VA (2021) Nanosafety vs. nanotoxicology: adequate animal models for testing in vivo toxicity of nanoparticles. Toxicology. 462:152952. https://doi.org/10.1016/j.tox.2021.15295210.1016/j.tox.2021.152952 ↗
93. Scimeca JC, Verron E (2022) Nano-engineered biomaterials: safety matters and toxicity evaluation. Mater Today Adv 15:100260. https://doi.org/10.1016/j.mtadv.2022.10026010.1016/j.mtadv.2022.100260 ↗
94. Halappanavar S, Ede JD, Mahapatra I, Krug HF, Kuempel ED, Lynch I, Vanderbriel RJ, Shatkin JA (2021) A methodology for developing key events to advance nanomaterial-relevant adverse outcome pathways to inform risk assessment. Nanotoxicology 15(3):289–310. https://doi.org/10.1080/17435390.2020.185141910.1080/17435390.2020.1851419 ↗
95. Xue HY, Liu S, Wong HL (2014) Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine 9(2):295–312. https://doi.org/10.2217/nnm.13.20410.2217/nnm.13.204 ↗
96. Shi J, Kantoff PW, Wooster R, Farokhzad OC (2017) Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 17(1):20–37. https://doi.org/10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
97. McNeil SE (2016) Evaluation of nanomedicines: stick to the basics. Nat Rev Mater 1(10):1–2. https://doi.org/10.1038/natrevmats.2016.7310.1038/natrevmats.2016.73 ↗
98. Metselaar JM, Lammers T (2020) Challenges in nanomedicine clinical translation. Drug Deliv Transl Res 10(3):721–725. https://doi.org/10.1007/s13346-020-00740-510.1007/s13346-020-00740-5 ↗
99. Zhang C, Yan L, Wang X, Zhu S, Chen C, Gu Z, Zhao Y (2020). Progress, challenges and future of nanomedicine. Nano Today 35. https://doi.org/10.1016/j.nantod.2020.10100810.1016/j.nantod.2020.101008 ↗
100. Gonzalez-Valdivieso J, Girotti A, Schneider J, Arias FJ (2021) Advanced nanomedicine and cancer: challenges and opportunities in clinical translation. Int J Pharm 599:120438. https://doi.org/10.1016/j.ijpharm.2021.12043810.1016/j.ijpharm.2021.120438 ↗